Balanced news tone
News Sentiment
BIIB34 sentiment intelligence
Biogen Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-7.5% over one week, +5.1% over four weeks, trend active, and near fair-value range.
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 14 Jul 2026 22:01
- Source
- GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- PR Newswire
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Biogen
FMR LLC's Strategic Acquisition of Biogen Inc Shares
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 11 Jun 2026 07:00
- Source
- GuruFocus
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 18 May 2026 07:00
- Source
- PR Newswire
Evercore ISI reinstates Biogen stock with Outperform rating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 14 May 2026 07:00
- Source
- Investing.com
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Biogen
Biogen stock hits 52-week high at $202.64
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- Investing.com
Biogen to Participate in the Bank of America Securities 2026 Health Care Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Biogen
Biogen stock price target raised to $245 by Canaccord on Apellis deal
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 01 Apr 2026 07:00
- Source
- Investing.com
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- Tone
- Positive 95/100
- Event
- Guidance
- Published
- 31 Mar 2026 07:00
- Source
- Biogen
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 31 Mar 2026 07:00
- Source
- Barchart.com
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Proactive financial news
Biogen stock maintained at Buy by Jefferies on FDA Spinraza approval
- Tone
- Positive 66/100
- Event
- Regulatory and legal
- Published
- 30 Mar 2026 07:00
- Source
- Investing.com
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Mar 2026 12:32
- Source
- Biogen
Biogen Completes Acquisition of Alcyone Therapeutics
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Nov 2025 08:00
- Source
- Biogen
Biogen to Acquire Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2023 07:00
- Source
- Biogen
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 09 Jun 2023 07:00
- Source
- Biogen